Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2

被引:119
作者
Lee, Hyun [1 ]
Whitfeld, Peter L. [2 ]
Mackay, Charles R. [1 ,2 ]
机构
[1] St Vincents Hosp, Garvan Inst Med Res, Immunol & Inflammat Dept, Darlinghurst, NSW 2010, Australia
[2] G2 Inflammat Pty Ltd, Darlinghurst, NSW, Australia
关键词
C5a; C5aR; C5L2;
D O I
10.1038/sj.icb.7100166
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Complement component C5a is one of the most potent inflammatory chemoattractants and has been implicated in the pathogenesis of numerous inflammatory diseases. C5a binds two receptors, C5aR and C5L2. Most of the C5a functional effects occur through C5aR, and the pharmaceutical industry has focused on this receptor for the development of new anti-inflammatory therapies. We used a novel approach to generate and test therapeutics that target C5aR. We created human C5aR knock-in mice, and used neutrophils from these to immunize wild-type mice. This yielded high-affinity blocking mAbs to human C5aR. We tested these anti-human C5aR mAbs in mouse models of inflammation, using the human C5aR knock-in mice. These antibodies completely prevented disease onset and were also able to reverse established disease in the K/B x N arthritis model. The physiological role of the other C5a receptor, C5L2 is still unclear, and our studies with blocking mAbs to human C5L2 have failed to demonstrate a clear functional role in signaling to C5a. The development of effective mAbs to human C5aR is an alternative approach to drug development, for this highly attractive target.
引用
收藏
页码:153 / 160
页数:8
相关论文
共 136 条
[1]   Contribution of anaphylatoxin C5a to late airway responses after repeated exposure of antigen to allergic rats [J].
Abe, M ;
Shibata, K ;
Akatsu, H ;
Shimizu, N ;
Sakata, N ;
Katsuragi, T ;
Okada, H .
JOURNAL OF IMMUNOLOGY, 2001, 167 (08) :4651-4660
[2]   C5a-induced gene expression in human umbilical vein endothelial cells [J].
Albrecht, EA ;
Chinnaiyan, AM ;
Varambally, S ;
Kumar-Sinha, C ;
Barrette, TR ;
Sarma, JV ;
Ward, PA .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (03) :849-859
[3]   Targeting C5a: Recent advances in drug discovery [J].
Allegretti, M ;
Moriconi, A ;
Beccari, AR ;
Di Bitondo, R ;
Bizzarri, C ;
Bertini, R ;
Colotta, F .
CURRENT MEDICINAL CHEMISTRY, 2005, 12 (02) :217-236
[4]  
AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139
[5]   The role of the complement system in ischemia-reperfusion injury [J].
Arumugam, TV ;
Shiels, IA ;
Woodruff, TM ;
Granger, DN ;
Taylor, SM .
SHOCK, 2004, 21 (05) :401-409
[6]   A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats [J].
Arumugam, TV ;
Shiels, IA ;
Strachan, AJ ;
Abbenante, G ;
Fairlie, DP ;
Taylor, SM .
KIDNEY INTERNATIONAL, 2003, 63 (01) :134-142
[7]   Critical role for the second extracellular loop in the binding of both orthosteric and allosteric g protein-coupled receptor Ligands [J].
Avlani, Vimesh A. ;
Gregory, Karen J. ;
Morton, Craig J. ;
Parker, Michael W. ;
Sexton, Patrick M. ;
Christopoulos, Arthur .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (35) :25677-25686
[8]  
BAO L, 1992, Genomics, V13, P437, DOI 10.1016/0888-7543(92)90265-T
[9]   C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist [J].
Bao, LH ;
Osawe, I ;
Puri, T ;
Lambris, JD ;
Haas, M ;
Quigg, RJ .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (08) :2496-2506
[10]   THE INHIBITION OF NEUTROPHIL GRANULE ENZYME-SECRETION AND CHEMOTAXIS BY PERTUSSIS TOXIN [J].
BECKER, EL ;
KERMODE, JC ;
NACCACHE, PH ;
YASSIN, R ;
MARSH, ML ;
MUNOZ, JJ ;
SHAAFI, RI .
JOURNAL OF CELL BIOLOGY, 1985, 100 (05) :1641-1646